Feature

Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery

Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

  • By

  • February 25, 2026

  • 2 min

Share

  • 1

    Syngene International collaborates with Johns Hopkins University.

  • 2

    Focus on early-stage drug discovery programs.

  • 3

    Uses Syngene SynVent™ platform for drug development.

  • 4

    Aims to compress drug development timelines.

  • 5

    Leverages Syngene’s Connector model to engage stakeholders.

  • 6

    Enhances the translation of academic research into therapeutic candidates.

Original Source(s)

Syngene and Johns Hopkins Partner to Advance Early-Stage Drug Discovery

Collaboration anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research

  • February 25, 2026

  • 2 min

Related Content

What Cats Can Tell Us About Cancer

Large-scale feline sequencing study highlights diagnostic and therapeutic targets shared with human cancers

  • February 25, 2026

  • 2 min
Making Laparoscopic Cholecystectomy Safer

Laparoscopic cholecystectomy has become the gold standard for gallbladder removal, with more than 750,000 procedures performed annually in the U.S.

  • by

  • February 24, 2026

  • 3 min
The Most Sensitive Cancer Blood Test Yet

A CRISPR-powered light sensor detected trace amounts of cancer biomarkers in the blood

  • February 24, 2026

  • 2 min